Y
Yasushi Seo
Researcher at Kobe University
Publications - 52
Citations - 1206
Yasushi Seo is an academic researcher from Kobe University. The author has contributed to research in topics: Hepatitis B virus & Hepatocellular carcinoma. The author has an hindex of 17, co-authored 52 publications receiving 1099 citations.
Papers
More filters
Journal ArticleDOI
Hepatitis C virus relapse was suppressed by long-term self-injection of low-dose interferon in patients with chronic hepatitis C after pegylated interferon plus ribavirin treatment.
Tomoyuki Takashima,Hirayuki Enomoto,Toshiaki Ninomiya,Soo Ryang Kim,Hiroaki Okushin,Masahiko Sugano,Susumu Imoto,Yoshihiko Yano,Teruji Ooka,Yasushi Seo,Hiroshi Kasugai,Akira Muramatsu,Hisato Jomura,Soji Shimomura,Michiko Shindo,Hideji Nakamura,Nobuhiro Aizawa,Yoshinori Iwata,Masaki Saito,Hiroyasu Imanishi,Hiroko Iijma,Shuhei Nishiguchi +21 more
TL;DR: The efficiencies and side‐effects of PEG IFN‐RBV and self‐injected low‐dose natural (n) IFN-α in patients with hepatitis C virus (HCV) are compared.
Journal ArticleDOI
NX-DCP as a novel biomarker would be related to liver function in cirrhotic patients with hepatocellular carcinoma.
TL;DR: It is first reported that novel des-g-carboxy prothrombin (DCP) would be much more related to liver function.
Journal ArticleDOI
Clinical significance of hepatitis B virus-DNA in hepatocellular carcinoma negative for hepatitis B virus surface antigen
Shinpei Tateiwa,Yoshihiko Yano,Yasushi Seo,Akira Miki,Kawano Yuuki,Takeshi Azuma,Yoshitake Hayashi +6 more
TL;DR: HBV may be associated with hepatocarcinogenesis in cases of occult HBV infection, and HBV-DNA was frequently detected in the liver tissues of NBNC-HCC.
Journal ArticleDOI
Letter: liver dysfunction and survival in hepatocellular carcinoma treated by transarterial chemoembolisation.
Masaya Saito,Yasushi Seo,Yoshihiko Yano,Akira Miki,Kenji Momose,Hirotaka Hirano,Masaru Yoshida,Takeshi Azuma +7 more
TL;DR: This research highlights the need to understand more fully the role of gut microbiota in the development of infectious disease and its role in immune response to antibiotics.
Journal ArticleDOI
Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon-α 2b and ribavirin) for genotype 1b chronic hepatitis C: The Kobe Hepatitis Therapeutic Group.
Fugui Bai,Yoshihiko Yano,Soo-Ryang Kim,Yasushi Seo,Akira Miki,Masaya Saito,Hirotaka Hirano,Kenji Momose,Akihiro Minami,Yuri Hatazawa,Takanobu Hayakumo,Dewiyani Indah Widasari,Hanggoro Tri Rinonce,Masahiko Sugano,Satoshi Tani,Seitetsu Yoon,Susumu Imoto,Takeshi Azuma,Hak Hotta,Yoshitake Hayashi +19 more
TL;DR: The IL28B SNP and mutations in the NS5A region were associated with the therapeutic response to triple therapy and pre-existing mutations in NS3 did not affect the efficacy of triple therapy.